Skip to main content
Smart Investors Daily
MB

NASDAQ · MBRX

Moleculin Biotech, Inc.

Healthcare · Biotechnology

$7.87

Down-$0.73 (-9.28%)

Updated Nov 17, 2026, 12:45 AM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
6.01M
P/E ratio
-0.18
Dividend yield
0.00%
52-week range
$0.16 – $12.19
Volume
9.9K
Avg. volume
194.99K

Price performance · MBRX

MBRX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

MBRX closed at $7.87 after 20 trading sessions, up 48.49% for the selected period.

Last close
$7.87
Period change
+48.49%
Period low
$5.30
Period high
$9.27
Daily close
View OHLC price history
MBRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$8.00$8.101$7.71$7.879.9K
Nov 12, 2026$8.77$8.90$7.90$8.0642.18K
Nov 11, 2026$8.08$8.40$8.00$8.1014.14K
Nov 10, 2026$8.51$8.87$8.01$8.0620.75K
Nov 9, 2026$8.83$8.88$8.52$8.6617.39K
Nov 6, 2026$8.88$8.94$8.53$8.7014.28K
Nov 5, 2026$8.46$8.96$7.74$8.7325.17K
Nov 4, 2026$8.13$8.6508$8.13$8.4613.78K
Nov 3, 2026$8.27$8.4199$8.27$8.3012.49K
Nov 2, 2026$7.96$8.50$7.65$8.3212.96K
Oct 30, 2026$8.80$9.00$7.90$7.9031.72K
Oct 29, 2026$8.70$8.84$8.079$8.7233.99K
Oct 28, 2026$9.41$10.24$8.10$8.745101.86K
Oct 27, 2026$7.18$9.7194$7.17$9.265188.86K
Oct 26, 2026$6.59$7.25$6.50$7.08525.46K
Oct 23, 2026$6.05$6.59$5.6483$6.5027.67K
Oct 22, 2026$6.13$6.1638$5.46$5.8959.13K
Oct 21, 2026$6.00$6.58$6.00$6.3142K
Oct 20, 2026$5.74$6.4025$5.24$6.19131.77K
Oct 19, 2026$5.60$5.60$4.42$5.3053.31K

Latest MBRX news

The latest Smart Investors Daily articles mentioning MBRX.

MBRX research

Overview

Company profile and research snapshot.

Company profile

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$170.00
Implied upside
—
Analysts
9
MBRX recent ratings
DateFirmRatingTarget
Aug 28, 2026HC Wainwright & Co.Buy—
Mar 24, 2026HC Wainwright & Co.Buy—
Dec 11, 2025HC Wainwright & Co.Buy—
Sep 10, 2025HC Wainwright & Co.Buy—
Aug 27, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 12, 2026

Moleculin Secures Australian Patent for Annamycin Formulation Technology

Patent strengthens intellectual property protection for preparation of preliposomal Annamycin lyophilizate HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced the grant of an Australian patent covering the preparation of preliposomal Annamycin lyophilizate, strengthening the Company’s intellectual property protection for a key aspect of Annamycin’s formulation technology. Australian Patent No. 2020303572 was granted to

Yahoo · Nov 10, 2026

Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies

Inhibition of CD8+ T cells shortens survival in Annamycin-treated mice, demonstrating the immune system is a functional contributor to Annamycin’s antitumor activity, not a bystander Annamycin achieves substantially higher pancreatic tissue exposure than doxorubicin, offering a potential explanation for why topoisomerase II, a validated target in pancreatic cancer, has never been successfully drugged there HOUSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Molecu

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.